<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592384</url>
  </required_header>
  <id_info>
    <org_study_id>31665-D</org_study_id>
    <secondary_id>H133A060107;</secondary_id>
    <nct_id>NCT00592384</nct_id>
  </id_info>
  <brief_title>Project to Improve Symptoms and Mood in People With Spinal Cord Injury</brief_title>
  <acronym>PRISMS</acronym>
  <official_title>A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shirley Ryan AbilityLab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor Health Care System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is likely the most prevalent and disabling psychological complication associated
      with spinal cord injury (SCI). Yet no controlled depression treatment trials have been
      performed in this population. The proposed study is a multi-site, randomized, double-blind,
      placebo controlled trial of venlafaxine XR (Effexor XR) in 133 adults with SCI and major
      depressive disorder (MDD) or dysthymia who are at least one month post injury. Participants
      will be recruited from four SCI Model System sites, the University of Washington,
      Rehabilitation Institute of Chicago, University of Michigan, University of Alabama,
      Birmingham and Baylor Institute for Rehabilitation, Dallas, TX. The purpose of the study is
      to examine the efficacy and tolerability of venlafaxine XR as a treatment for MDD. The
      primary outcome will be the percent of responders (those who report at least a 50% reduction
      in depression severity from baseline to the end of treatment) in the venlafaxine XR versus
      placebo control group using intent-to-treat analysis. Secondary outcomes will include changes
      in pain, health related quality of life depression-related disability and community
      participation. A successful clinical trial could lead to more aggressive identification and
      treatment of MDD as well as improved health and quality of life in this important population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is likely the most prevalent and disabling psychological complication associated
      with spinal cord injury (SCI). The prevalence of major depression in people with SCI is 22%
      or two to six times higher than in the general population. Depression is linked to a myriad
      of adverse outcomes including poor subjective health, poor community integration, higher
      rates of medical complications and high rates of suicide. Surprisingly there are no
      randomized controlled trials for treating major depressive disorder (MMD) in people with SCI.
      Despite the widespread use of antidepressants in this population, the common assumption that
      antidepressant medications are effective and well-tolerated among people with SCI is
      uncertain. Multiple factors such as severe stresses, bereavement and loss of rewarding
      activities may complicate treatment. Treatment trials suggest antidepressants may not be as
      effective in people with medical/neurological conditions as they are with depression that
      develops as a primary condition. For almost 20 years clinicians and scientists have called
      for controlled clinical trials of antidepressants among people with SCI in order to establish
      evidence-based treatment. The proposed study is a multi-site, randomized, double-blind,
      placebo controlled trial of venlafaxine XR (Effexor XR) in 133 adults with SCI and MDD or
      dysthymia who are at least one month post injury. Participants aged 18-64 will be recruited
      from four SCI Model System sites, the University of Washington, Rehabilitation Institute of
      Chicago, University of Michigan, University of Alabama, Birmingham and Baylor Institute for
      Rehabilitation, Dallas TX. The purpose of the study is to examine the efficacy and
      tolerability of venlafaxine XR as a treatment for MDD. The primary outcome will be the
      percent of responders (those who report at least a 50% reduction in depression severity from
      baseline to the end of treatment) in the venlafaxine XR versus placebo control group using
      intent-to-treat analysis. Secondary outcomes will include changes in pain, health related
      quality of life and participation. A successful clinical trial could lead to more aggressive
      identification and treatment of MDD as well as improved health and quality of life in this
      important population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale-17</measure>
    <time_frame>0 weeks, 12 weeks</time_frame>
    <description>The 17-item Hamilton Depression Rating Scale is a clinician rated measure of depression severity (we used a structured interview version (Williams 1988) to improve inter-rater reliability). Scores range from 0-52. Higher scores indicate more severe depression. Scores of 7 or less indicate remission from depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale-Maier Subscale</measure>
    <time_frame>0 weeks, 12 weeks</time_frame>
    <description>The Maier is a 6-item sub scale of the Hamilton derived from Rasch analysis. It is a unidimensional scale with superior sensitivity to change. It excludes somatic items and is therefore especially appropriate for individuals who have substantial physical impairment and medical comorbidity. Scores can range from 0-22 with higher scores indicating more severe depression. Scores of 4 or less indicated in remission from depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist-20 Depression Subscale</measure>
    <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory</measure>
    <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Ashworth Spasticity Scale</measure>
    <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Structured Clinical Interview for DSM IV Depression Module</measure>
    <time_frame>Weeks 0, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>Weeks 0, 12, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects Checklist</measure>
    <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craig Handicap and Reporting Technique</measure>
    <time_frame>Weeks 0, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Life</measure>
    <time_frame>Weeks 0, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale</measure>
    <time_frame>Weeks 0, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression</measure>
    <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression</measure>
    <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Rating Scale for Anxiety</measure>
    <time_frame>Weeks 0, 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Dysthymia</condition>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>venlafaxine XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>venlafaxine XR 37.5 - 300 mg/day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine XR</intervention_name>
    <description>Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg</description>
    <arm_group_label>venlafaxine XR</arm_group_label>
    <other_name>Effexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>identically encapsulated inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Spinal cord injury (ASIA A-D)

          -  At least one month post injury

          -  Meets DSM IV criteria for major depression or dysthymia on the SCID

          -  At least moderately severe depression (PHQ-9 score &gt;= 10)

          -  Within reasonable travel distance to one of the study sites

        Exclusion Criteria:

          -  Current DSM IV alcohol or drug dependence

          -  History of bipolar disorder or psychosis

          -  History of &gt;= 2 suicide attempts or suicide attempt with 5 years

          -  Current suicidal intent or plan

          -  Medical contraindications

          -  Non-English speaker

          -  Clinically significant cognitive/language impairment

          -  History of allergic reaction to venlafaxine XR or use of MAO-I with 2 weeks

          -  Current use of antidepressant medications (will not exclude if on low dose of a
             tricyclic antidepressant or trazodone for pain, sleep, or bladder), psychotherapy for
             depression, or electroconvulsive therapy

          -  Pregnant or lactating women or women of childbearing potential who are not willing to
             use a reliable form of contraception

          -  Unstable medical condition, as determined by physical examination, CBC w/ platelets
             (including hematocrit, hemoglobin, WBC, differential), serum chemistry panel (serum
             sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose), liver
             transaminases (AST, ALT), thyroid stimulating hormone (TSH), urinalysis, supine
             diastolic blood pressure (SDBP) &gt; 90 mm Hg, or near terminal illness (primary care
             physician estimates that patient has &lt; 1 year to live)

          -  Anticipated major surgical procedures within the 12 weeks of randomization

          -  Use of an investigational drug within 30 days

          -  Use of psychoactive medications, including corticosteroids and anticonvulsants, that
             have not been at a stable dose for at least 2 weeks

          -  Use of anxiolytic, sedative-hypnotic, or other psychotropic drug or substance
             (including St. John's Wort) within 7 days of start of double-blind treatment. If the
             patient is taking a sedative deemed necessary for sleep induction or spasticity, the
             dosage must have been stable for at least 2 weeks. Use of anticholinergic, low-dose
             tricyclic antidepressant, GABAergic or adrenergic medications for spasticity are
             permitted if at a stable dose for at least 2 weeks.

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles H. Bombardier, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington School of Medicine, Department of Rehabilitation Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesse R. Fann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington School of Medicine, Department of Psychiatry and Behavioral Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehabilitation Institute of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0491</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Institute for Rehabilitation</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington/Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2008</study_first_submitted>
  <study_first_submitted_qc>January 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <results_first_submitted>June 11, 2014</results_first_submitted>
  <results_first_submitted_qc>December 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2015</results_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Charles Bombardier</investigator_full_name>
    <investigator_title>Primary Investigator</investigator_title>
  </responsible_party>
  <keyword>spinal cord injuries</keyword>
  <keyword>major depressive disorder</keyword>
  <keyword>dysthymia</keyword>
  <keyword>antidepressant agents</keyword>
  <keyword>pain</keyword>
  <keyword>quality of life</keyword>
  <keyword>muscle spasticity</keyword>
  <keyword>community participation</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Dysthymic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Control</title>
          <description>placebo: identically encapsulated inactive substance</description>
        </group>
        <group group_id="P2">
          <title>Venlafaxine XR</title>
          <description>venlafaxine XR: Once daily oral dose ranging from 37.5 mg up to 300 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Control</title>
          <description>placebo: identically encapsulated inactive substance</description>
        </group>
        <group group_id="B2">
          <title>Venlafaxine XR</title>
          <description>venlafaxine XR: Once daily oral dose ranging from 37.5 mg up to 300 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="133"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="12"/>
                    <measurement group_id="B2" value="39" spread="11"/>
                    <measurement group_id="B3" value="40" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale-17</title>
        <description>The 17-item Hamilton Depression Rating Scale is a clinician rated measure of depression severity (we used a structured interview version (Williams 1988) to improve inter-rater reliability). Scores range from 0-52. Higher scores indicate more severe depression. Scores of 7 or less indicate remission from depression.</description>
        <time_frame>0 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>placebo: identically encapsulated inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR</title>
            <description>venlafaxine XR: Once daily oral dose ranging from 37.5 mg up to 300 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale-17</title>
          <description>The 17-item Hamilton Depression Rating Scale is a clinician rated measure of depression severity (we used a structured interview version (Williams 1988) to improve inter-rater reliability). Scores range from 0-52. Higher scores indicate more severe depression. Scores of 7 or less indicate remission from depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="5.4"/>
                    <measurement group_id="O2" value="19.4" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-week outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="6.5"/>
                    <measurement group_id="O2" value="9.5" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary analyses included observations at baseline, 1, 3, 6, 8, 10, and 12 weeks. Random effects were included for participants’ intercepts. Fixed effects were time (linear), treatment (VFN vs. PBO), interaction of time with treatment, stratification factors and potential confounders and variables to improve sensitivity. The primary indicator of treatment effect was the interaction of time by treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.025</p_value>
            <p_value_desc>Bonferroni corrected for two primary comparisons</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>see above</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Checklist-20 Depression Subscale</title>
        <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory</title>
        <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Ashworth Spasticity Scale</title>
        <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Structured Clinical Interview for DSM IV Depression Module</title>
        <time_frame>Weeks 0, 12, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12</title>
        <time_frame>Weeks 0, 12, 24</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects Checklist</title>
        <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Craig Handicap and Reporting Technique</title>
        <time_frame>Weeks 0, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Life</title>
        <time_frame>Weeks 0, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sheehan Disability Scale</title>
        <time_frame>Weeks 0, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression</title>
        <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression</title>
        <time_frame>Weeks 0, 1, 3, 6, 8, 10, 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hamilton Rating Scale for Anxiety</title>
        <time_frame>Weeks 0, 12</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale-Maier Subscale</title>
        <description>The Maier is a 6-item sub scale of the Hamilton derived from Rasch analysis. It is a unidimensional scale with superior sensitivity to change. It excludes somatic items and is therefore especially appropriate for individuals who have substantial physical impairment and medical comorbidity. Scores can range from 0-22 with higher scores indicating more severe depression. Scores of 4 or less indicated in remission from depression.</description>
        <time_frame>0 weeks, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Control</title>
            <description>placebo: identically encapsulated inactive substance</description>
          </group>
          <group group_id="O2">
            <title>Venlafaxine XR</title>
            <description>venlafaxine XR: Once daily oral dose ranging from 37.5 mg up to 300 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale-Maier Subscale</title>
          <description>The Maier is a 6-item sub scale of the Hamilton derived from Rasch analysis. It is a unidimensional scale with superior sensitivity to change. It excludes somatic items and is therefore especially appropriate for individuals who have substantial physical impairment and medical comorbidity. Scores can range from 0-22 with higher scores indicating more severe depression. Scores of 4 or less indicated in remission from depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="2.8"/>
                    <measurement group_id="O2" value="9.1" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-week outcome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="3.5"/>
                    <measurement group_id="O2" value="3.5" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary analyses included observations at baseline, 1, 3, 6, 8, 10, and 12 weeks. Random effects were included for participants’ intercepts. Fixed effects were time (linear), treatment (VFN vs. PBO), interaction of time with treatment, stratification factors and potential confounders and variables to improve sensitivity. The primary indicator of treatment effect was the interaction of time by treatment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.025</p_value>
            <p_value_desc>Bonferroni corrected for two primary outcomes</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected at each interim visit (weeks 1, 3, 6, 8, 10) and at the final outcome point (12 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Control</title>
          <description>placebo: identically encapsulated inactive substance</description>
        </group>
        <group group_id="E2">
          <title>Venlafaxine XR</title>
          <description>venlafaxine XR: Once daily oral dose ranging from 37.5 mg up to 300 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>self-harm</sub_title>
                <description>Subject had self-inflicted knife wound to abdomen</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>heart palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blurry vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>increased spasticity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>increased risk of suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection and pressure ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jesse R. Fann</name_or_title>
      <organization>University of Washington</organization>
      <phone>206 6854280</phone>
      <email>fann@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

